Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Condition:   Ischemic Heart Disease
Interventions:   Drug: GS-6615;   Drug: Placebo
Sponsor:   Gilead Sciences
Not yet recruiting - verified February 2015

Benefits of Exercise Training in Women With Ischemic Syndrome

Condition:   Microvascular Coronary Dysfunction
Intervention:   Behavioral: Exercise training
Sponsor:   Cedars-Sinai Medical Center
Not yet recruiting - verified February 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Not yet recruiting - verified February 2015

Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: GS-6615;   Drug: Placebo
Sponsor:   Gilead Sciences
Recruiting - verified February 2015

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Exploring the Mechanism of the Plaque Rupture in Acute Myocardial Infarction

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Plaque, Atherosclerotic;   Rupture, Spontaneous
Intervention:  
Sponsors:   Seoul National University Hospital;   HeartFlow, Inc.;   Kyoto University, Graduate School of Medicine;   Inje University;   Keimyung University Dongsan Medical Center;   Ulsan University Hospital;   Wakayama Medical University;   Aarhus University Hospital
Recruiting - verified February 2015

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified February 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

Renal Denervation in Patients After Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Arterial Hypertension
Interventions:   Procedure: Renal denervation;   Drug: Metoprolol;   Drug: Lisinopril
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified March 2015

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Condition:   Non-ST or ST Elevation Acute Coronary Syndromes
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   AstraZeneca
Completed - verified February 2015

The TRUST Study - Depression Substudy

Conditions:   Subclinical Hypothyroidism;   Depression
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   Leiden University Medical Center;   University of Bern
Recruiting - verified February 2015

The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease

Conditions:   Myocardial Infarction;   Unstable Angina
Intervention:  
Sponsors:   Massachusetts General Hospital;   University of California, Berkeley
Completed - verified February 2015

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified February 2015

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2015

Tryptase and Coronary Heart Disease

Conditions:   Acute Coronary Syndrome With ST Elevation on Electrocardiogram;   Acute Coronary Syndrome Without ST Elevation on Electrocardiogram;   Noncritical Coronary Artery Disease With Coronary Stenosis <50%;   Aortic Aneurysms
Intervention:  
Sponsor:   Niguarda Hospital
Recruiting - verified February 2015

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Conditions:   Obesity;   Overweight
Interventions:   Drug: NB32;   Drug: PBO;   Behavioral: Weight Management Program
Sponsor:   Takeda
Active, not recruiting - verified February 2015

Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial

Condition:   Coronary Artery Disease
Interventions:   Procedure: LIMA to SVG Bridge Technique;   Procedure: Conventional CABG
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified February 2015

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified February 2015

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Modification of Prasugrel based on a biological assay;   Drug: prasugrel / clopidogrel;   Device: Verify Now
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Allies in Cardiovascular Trials Initiatives and Organized Networks:ACTION;   Accumetrics, Inc.;   Stentys
Recruiting - verified February 2015

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Anesthesia;   Pain;   Reflux;   Nausea;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma
Intervention:   Drug: Ampicillin
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation
Recruiting - verified February 2015

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified March 2015

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified March 2015

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease

Conditions:   Atherosclerosis;   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Coronary intervention using IVUS-VH & FDG PET-MDCT;   Device: Coronary intervention using IVUS-VH & FDG PET-MDCT
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Institut National de la Santé Et de la Recherche Médicale, France
Completed - verified February 2015

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified March 2015

Sitagliptin Cardiovascular Outcome Study (MK-0431-082)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Active, not recruiting - verified February 2015

French Registry of Acute Coronary Syndrome

Condition:   Acute Myocardial Infarction
Intervention:   Other: Blood sample
Sponsors:   Assistance Publique - Hôpitaux de Paris;   French Cardiology Society
Active, not recruiting - verified October 2014

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified March 2015

Get CardioSmart

You're Invited